Hunter Capital RTO 1 agrees to acquire ResoTher Pharma

• Hunter Capital RTO 1 has agreed to acquire Denmark's ResoTher Pharma in exchange for newly issued shares.
• The transaction values ResoTher Pharma at approximately SEK 273 million, implying a combined valuation of approximately SEK 333 million.
• ResoTher Pharma shareholders would own approximately 82% of the combined company; existing shareholders of the buyer would retain approximately 18%.
• Transaction-related financing totals approximately SEK 80 million, including a SEK 32 million convertible loan facility conditional on completion.
• The combined company will operate ResoTher Pharma's biotechnology business, with lead heart-attack treatment candidate RTP-026 preparing for a Phase 2b trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hunter Capital RTO 1 AB (publ) published the original content used to generate this news brief via Cision (Ref. ID: 202610280430BITN____UKPR__SV_20261027-BIT-0886-0) on October 28, 2026, and is solely responsible for the information contained therein.